2
16
↑2
↓16
—0
Evidence suggests Semaglutide maydecreaseHemoglobin a1c.
14 studies (18 claims)
Moderate consensus
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| 24 weeks of semaglutide treatment | Decreases - significant improvements in | glycated hemoglobin level | Human | patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) | Not specified in the abstract. | Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.cited 30× |
| high-dose semaglutide (2 mg) | Decreases - reveal significant reductions in | hemoglobin A1C levels | Human | — | — | Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons. |
| once-weekly cagrilintide-semaglutide (2.4 mg each) | Decreases - percentage of patients who had | glycated hemoglobin level of 6.5% or less | Human | patients | — | Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. |
| subcutaneous semaglutide | Decreases - decreased | hemoglobin A1c (HbA1c) level | Human | patients with type 2 diabetes | — | Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. |
| oral semaglutide | Decreases - decreased | hemoglobin A1c (HbA1c) level | Human | patients with type 2 diabetes | — | Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. |
| oral semaglutide | Decreases - reductions were significant vs placebo | hemoglobin A1c (HbA1c) level | Human | patients with type 2 diabetes | — | Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. |
| semaglutide | Decreases - reduced | hemoglobin A1c | Human | adult with CFRD, obesity, and clinical insulin resistance | — | Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome. |
| semaglutide | Increases - later experienced | hemoglobin A1C (HbA1c) levels | Human | a 36-year-old man with a history of type 2 diabetes mellitus (T2DM) and prior plantar necrotizing fasciitis | — | Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report. |
| Semaglutide | Decreases - significantly reduced | hemoglobin A1c (HbA1c) levels | Human | patients | — | Comparative effectiveness of semaglutide |
| semaglutide at a dose of 1 mg | Decreases - estimated mean change from baseline | glycated hemoglobin level | Human | patients with type 2 diabetes | — | Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. |
| once-weekly subcutaneous semaglutide 2.4 mg | Decreases - positive changes | glycated hemoglobin (HbA1c) | Human | people with obesity | Once-weekly subcutaneous semaglutide 2.4 mg. | Cardiometabolic risk factors efficacy of semaglutide in the STEP program.cited 3× |
| oral semaglutide | Decreases - reduced | glycated hemoglobin | Human | patients with uncontrolled T2D on various background therapies | Not applicable. | Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?cited 16× |
| injectable semaglutide or tirzepatide | Decreases - mean (SD) absolute reduction in percent glycated hemoglobin at 1 year was | glycated hemoglobin | Human | adults with overweight or obesity without type 2 diabetes with early discontinuation | — | Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. |
| injectable semaglutide or tirzepatide | Decreases - mean (SD) absolute reduction in percent glycated hemoglobin at 1 year was | glycated hemoglobin | Human | adults with overweight or obesity without type 2 diabetes with late discontinuation | — | Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. |
| injectable semaglutide or tirzepatide | Decreases - mean (SD) absolute reduction in percent glycated hemoglobin at 1 year was | glycated hemoglobin | Human | adults with overweight or obesity without type 2 diabetes with non-discontinuation | — | Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. |